inonotu
obliquu
polysaccharid
iop
potenti
drug
prevent
treatment
cancer
cardiopathi
diabet
aid
pancreat
diseas
studi
found
iop
act
broadspectrum
antivir
drug
felin
virus
vitro
experi
use
cell
model
felin
caliciviru
fcv
demonstr
iop
treatment
capabl
exhibit
antifcv
strain
activ
cellbas
assay
also
show
low
cytotox
investig
mechan
action
compound
reveal
iop
treatment
induc
inhibitori
action
directli
viru
particl
block
viral
bindingabsorpt
inhibitori
activ
fcv
isol
china
also
identifi
importantli
found
iop
exhibit
broadspectrum
antivir
activ
felin
herpesviru
felin
influenza
viru
felin
panleukopenia
viru
felin
infecti
periton
viru
contribut
respiratori
gastrointestin
diseas
cat
find
suggest
iop
may
potenti
broadspectrum
antivir
drug
felin
virus
respiratori
gastrointestin
virus
felin
caliciviru
fcv
felin
herpesviru
felin
influenza
viru
fiv
felin
panleukopenia
viru
fpv
felin
infecti
periton
viru
fipv
main
caus
contribut
acut
chronic
infect
cat
current
widespread
vaccin
project
perform
preval
virus
remain
high
due
main
antigen
chang
emerg
new
virus
immun
serum
contain
viral
antibodi
use
prevent
infect
suscept
anim
howev
method
current
wide
appli
felin
recombin
interferonomega
effect
treatment
felin
leukemia
viru
felv
fcov
infect
cat
also
inhibit
viral
replic
canin
parvoviru
remain
unclear
effect
treatment
inhibit
felin
viral
infect
mefloquin
small
molecul
inhibitor
demonstr
effect
antivir
drug
fcov
fcv
replic
vitro
experi
previou
studi
show
licl
germacron
effici
inhibit
fcv
replic
vitro
howev
broadspectrum
antivir
activ
inhibitor
need
investig
urgent
develop
effect
safe
broadspectrum
antivir
drug
felin
viral
diseas
inonotu
obliquu
io
also
known
chaga
whiterot
fungu
belong
hymenochaetaxea
famili
basidiomycotina
parasit
betula
birch
trunk
low
latitud
approxim
n
asia
europ
north
america
clinic
anim
experi
demonstr
io
polysaccharid
may
potenti
drug
prevent
cure
cancer
cardiopathi
diabet
aid
pancreat
diseas
io
fungu
water
extract
show
virucid
activ
toward
hepat
c
viru
suggest
potenti
applic
antivir
research
howev
crude
extract
main
antivir
factor
remain
unknown
moreov
crude
extract
may
potenti
exhibit
stronger
toxic
evalu
antivir
effect
io
polysaccharid
iop
toward
multifelin
respiratori
gastrointestin
virus
felin
caliciviru
fcv
felin
herpesviru
felin
influenza
viru
fiv
felin
panleukopenia
viru
fpv
felin
infecti
periton
viru
fipv
result
reveal
iop
possess
broadspectrum
activ
felin
rnaand
dnavirus
preliminari
mechan
reveal
iop
act
target
viru
entri
iop
gift
professor
juanjuan
qu
colleg
resourc
environment
scienc
northeast
agricultur
univers
prepar
iop
describ
previous
initi
dissolv
dmem
concentr
mgml
ribavin
purchas
sigmaaldrich
sigma
st
loui
mo
usa
crandellrees
felin
kidney
crfk
cell
madindarbi
canin
kidney
mdck
cell
atcc
grown
dulbecco
modifi
eagl
medium
dmem
gibco
contain
fetal
bovin
serum
fb
penicillinstreptomycin
cell
incub
c
co
humidifi
cabinet
fcv
fpv
fipv
propag
titrat
crfk
cell
propag
embryon
specialpathogenicfre
spf
chicken
egg
titrat
crfk
cell
propag
titrat
mdck
cell
recombin
fcv
strain
express
egfp
rfcvegfp
produc
lab
egfp
insert
n
terminu
recombin
fhv
strain
express
egfp
rfhvegfp
produc
use
homolog
recombin
method
gene
replac
cmvegfp
express
cassett
recombin
virus
produc
lab
cell
inocul
plate
cellswel
prior
assay
next
day
iop
ribavin
differ
concentr
dilut
dmem
contain
fb
ad
cell
cell
treat
dmem
contain
fb
use
control
follow
treatment
h
cytotox
assay
perform
use
cell
count
donjindo
japan
wash
three
time
pb
solut
l
dmem
l
ad
cell
plate
incub
c
two
hour
optic
densiti
od
determin
enspir
multimod
plate
reader
pe
usa
nm
excit
filter
rel
cell
viabil
calcul
percentag
control
cell
cell
inocul
plate
cellswel
prior
assay
next
day
iop
ribavin
differ
concentr
ad
cell
follow
h
treatment
virus
dilut
dmem
presenc
drug
ad
cell
h
cell
wash
three
time
cell
inocul
medium
contain
iop
h
cpe
observ
control
cell
supernat
harvest
viral
titrat
cell
wash
three
time
medium
contain
gml
resazurin
lwell
ad
h
incub
fluoresc
signal
measur
enspir
multimod
plate
reader
pe
usa
use
nm
excit
filter
nm
emiss
filter
percentag
inhibit
cpe
calcul
fluoresc
intens
infect
cell
treat
iop
b
fluoresc
intens
infect
cell
untreat
iop
c
fluoresc
intens
uninfect
cell
untreat
iop
prepar
cell
applic
strategi
drug
infect
describ
cpe
inhibit
assay
cell
infect
rfcvegfp
rfhvegfp
fluoresc
intens
assay
perform
h
postinfect
hpi
determin
stage
viral
life
cycl
inhibit
iop
antivir
activ
pretreat
simultan
treatment
posttreat
manner
investig
cell
seed
plate
cellswel
cultur
h
cell
pretreat
iop
concentr
gml
two
hour
incub
cell
inocul
strain
moi
one
hour
absorpt
medium
replac
fresh
dmem
contain
fb
gml
iop
cell
simultan
expos
strain
moi
iop
gml
one
hour
absorpt
medium
replac
fresh
dmem
contain
fb
gml
iop
cell
inocul
strain
moi
h
prior
exposur
gml
iop
hpi
recov
viru
yield
cell
supernat
determin
hpi
level
vrna
examin
realtim
rtpcr
accord
method
describ
previous
protocol
viru
titrat
describ
previou
studi
briefli
tenfold
dilut
viru
stock
prepar
cell
inocul
ml
dilut
h
absorpt
supernat
discard
fresh
dmem
contain
fb
penicillinstreptomycin
ad
well
cytopatholog
hpi
observ
viral
titer
express
median
tissu
cultur
infect
dose
log
tcid
ml
accord
method
reed
fpv
infect
experi
viral
replic
determin
via
direct
fluoresc
assay
dfa
use
fitcconjug
anticanin
parvoviru
monoclon
antibodi
cjfcpvmab
vmrd
data
present
mean
standard
deviat
sd
statist
signific
determin
use
unpair
test
oneway
anova
prism
softwar
graphpad
softwar
test
valu
p
consid
indic
signific
differ
recombin
fcv
express
green
fluoresc
protein
rfcvegfp
report
viru
replic
use
analyz
iop
inhibitor
fcv
replic
shown
fig
found
iop
treatment
reduc
fluoresc
intens
depend
dose
iop
reveal
iop
may
act
potent
inhibitor
fcv
next
cytotox
iop
evalu
crfk
cell
use
assay
cytotox
concentr
cc
determin
greater
mgml
h
incub
period
fig
suggest
treatment
exhibit
low
cytotox
pretreat
differ
concentr
iop
c
ribavirin
f
h
infect
strain
variou
moi
presenc
iop
cpe
inhibit
assay
perform
use
resazurinbas
method
hpi
cell
viabil
determin
use
assay
g
accord
method
describ
c
f
viru
yield
reduct
supernat
ioptreat
cell
ribavirintr
cell
g
cell
viabil
hpi
determin
result
repres
mean
three
replic
sd
experi
repeat
three
time
evalu
antifcv
activ
resazurinbas
cpe
inhibit
assay
describ
previous
use
titrat
iop
show
concentrationrespons
relationship
show
nearli
inhibit
cytopath
effect
cpe
concentr
gml
inhibit
concentr
gml
cell
infect
moi
fig
number
virus
expos
cell
increas
abil
inhibit
format
cpe
decreas
inhibitori
concentr
ic
increas
gml
moi
gml
moi
moreov
signific
therapeut
index
ti
cc
ic
valu
iop
rang
determin
cpe
inhibit
associ
signific
reduct
progeni
virion
load
concentrationdepend
inhibit
viral
replic
also
demonstr
assay
moi
moi
fig
compar
control
cell
viral
titer
iop
gml
treat
cell
reduc
log
moi
log
moi
calcul
ic
shown
fig
experi
ribavirin
known
polymeras
inhibitor
rna
virus
includ
posit
control
cytotox
test
ribavirin
crfk
cell
show
treatment
exhibit
low
toxiti
h
postinocul
exhibit
signific
toxiti
h
postinocul
fig
cc
determin
g
fig
resazurinbas
cpe
inhibit
assay
ic
determin
gml
moi
gml
moi
fig
viru
yield
reduct
assay
ic
determin
gml
moi
gml
moi
fig
antivir
activ
ribavirin
potent
iop
vitro
toxic
test
reveal
ribavirin
exhibit
higher
toxic
iop
determin
step
viral
replic
disrupt
antivir
activ
pretreat
h
simultan
treatment
h
posttreat
h
h
investig
hpi
viral
rna
level
viral
yield
determin
iop
treatment
significantli
reduc
viral
rna
level
time
point
fig
cell
expos
iop
time
exposur
iop
delay
inhibitori
abil
decreas
cell
expos
iop
hpi
reduct
detect
fig
result
viral
titer
assay
also
show
similar
trend
fig
iop
addit
h
h
significantli
inhibit
viral
replic
fig
viral
rna
level
reduc
cell
expos
iop
h
viral
titrat
test
show
viral
product
significantli
decreas
fig
investig
mechan
antifcv
activ
iop
antifcv
activ
viru
pretreat
cell
pretreat
viruscel
simultan
inocul
compar
investig
whether
antifcv
activ
iop
result
activ
cellular
factor
cell
pretreat
iop
cell
cpa
treat
group
infect
fcv
presenc
iop
cell
cpb
treat
group
infect
fcv
without
iop
shown
fig
viral
rna
level
viral
titer
cpa
treat
group
significantli
lower
mock
group
level
reduc
cpb
treat
group
cell
pretreat
iop
indic
antifcv
activ
iop
may
result
activ
host
factor
iop
treatment
next
examin
whether
iop
treatment
induc
inhibitori
action
directli
viru
particl
mixtur
contain
viru
iop
incub
c
one
hour
ad
cell
vta
treat
group
onehour
absorpt
period
cell
continu
kept
presenc
iop
vtb
treat
group
receiv
iop
medium
viral
rna
level
viral
titer
vta
vtb
treat
group
significantli
lower
mock
group
signific
differ
observ
vta
vtb
treat
group
fig
vsa
vsb
group
mixtur
contain
viru
iop
directli
ad
cell
vsa
treat
group
onehour
absorpt
period
cell
continu
kept
presenc
iop
vsb
treat
group
receiv
iop
medium
result
comparison
vsa
treat
group
similar
vta
vtb
treat
group
indic
iop
treatment
may
affect
viral
bindingabsorpt
cell
directli
iop
display
high
antivir
activ
refer
strain
fcv
analyz
antivir
activ
field
fcv
isol
cpeinhibit
viru
yield
reduct
assay
perform
shown
fig
nearli
inhibit
cpe
induc
field
isol
observ
concentr
gml
shown
fig
iop
treatment
led
log
reduct
product
field
isol
virus
investig
whether
iop
display
broadspectrum
antivir
activ
examin
replic
virus
wide
circul
cat
popul
presenc
iop
tabl
iop
treatment
led
inhibit
cpe
induc
fhv
exhibit
concentrationrespons
effect
fig
ic
valu
determin
gml
tabl
presenc
iop
gml
gml
viral
titer
decreas
log
fig
visual
inhibitori
effect
iop
fhv
replic
recombin
fhv
express
egfp
use
shown
fig
supplementari
materi
found
iop
treatment
reduc
fluoresc
intens
depend
dose
iop
moreov
iop
treatment
also
suppress
cpe
induc
fcov
infect
fig
fpv
infect
fig
fiv
fig
fig
subtyp
infect
compar
control
exposur
gml
iop
led
log
fig
log
fig
log
fig
log
fig
reduct
viru
titer
respect
current
rivavirin
nucleotid
analogu
nonspecif
inhibitor
dnarna
synthesi
exhibit
broadspectrum
antivir
activ
applic
antivir
compound
idoxuridin
deoxyuridin
trifluorothymidin
deoxyuridin
may
affect
normal
biolog
process
requir
host
toxic
administ
system
antivir
activ
sever
sulfat
polysaccharid
heparin
dextran
sulfat
pentosan
polysulf
mannan
sulfat
sulfat
cyclodextrin
demonstr
variou
envelop
virus
includ
herp
simplex
viru
hsv
human
cytomegaloviru
human
immunodefici
viru
hiv
simian
immunodefici
viru
flavivirus
extract
ulva
fasciata
inhibit
infect
japanes
enceph
viru
jev
describ
properti
biolog
macromolecular
inonotu
obliquu
polysaccharid
iop
inhibit
broad
spectrum
felin
virus
current
circul
wide
cat
studi
found
iop
potent
inhibit
least
five
differ
famili
includ
rna
virus
calicivirida
coronavirida
orthomyxovirida
dna
virus
alphaherpesvirina
parvoviru
tabl
visual
inhibitori
effect
iop
cpa
group
medium
chang
strain
moi
directli
ad
cpb
group
cell
wash
viru
moi
ad
onehour
absorpt
c
fresh
dmem
contain
fb
ad
cpa
cpb
group
vta
vtb
group
l
iop
gml
dmem
mock
l
strain
moi
ad
cell
mix
incub
c
one
hour
mixtur
ad
cell
onehour
absorpt
c
cell
wash
fresh
dmem
contain
fb
iop
gml
contain
fb
ad
vta
vtb
group
respect
vsa
vsb
group
l
iop
gml
dmem
mock
l
strain
moi
ad
cell
mix
mixtur
directli
ad
cell
onehour
absorpt
c
cell
wash
fresh
dmem
contain
fb
iop
gml
contain
fb
ad
vsa
vsb
group
respect
viral
rna
c
titer
analyz
hpi
result
repres
mean
three
replic
sd
experi
repeat
three
time
data
overview
cellbas
experi
evalu
antivir
efficaci
overal
toxic
iop
antivir
activ
iop
detect
use
multipl
unrel
virus
differ
cell
type
recombin
fcv
fhv
express
egfp
use
iop
treatment
reduc
fluoresc
intens
infect
vitro
timeofaddit
experi
perform
fcv
suggest
earli
stage
viral
replic
affect
iop
varieti
differ
viru
famili
inhibit
iop
appear
like
potenti
cellular
factor
essenti
viral
replic
activ
howev
found
iop
treatment
induc
inhibitori
action
directli
viru
particl
may
affect
viral
bindingabsorpt
cell
directli
previou
clinic
anim
experi
demonstr
iop
may
potenti
drug
prevent
cure
cancer
cardiopathi
diabet
aid
pancreat
diseas
describ
broadspectrum
antivir
effect
iop
toward
multifelin
virus
felin
caliciviru
fcv
felin
herpesviru
felin
influenza
viru
fiv
felin
panleukopenia
viru
fpv
felin
coronaviru
fcov
moreov
iop
show
low
cytotox
cc
determin
mgml
ic
virus
studi
rang
gml
gml
notabl
iop
treatment
show
toxic
effect
mous
major
organ
liver
evalu
histopatholog
examin
data
indic
iop
might
potenti
felin
antivir
agent
due
broadspectrum
antivir
activ
low
toxic
iop
caus
default
viral
entri
possibl
iop
act
virion
andor
cell
receptor
felin
virus
investig
member
rna
dna
viral
famili
mani
use
entri
mechan
previou
studi
indic
extract
ulva
fasciata
inhibit
jev
infect
form
complex
block
viru
adsorpt
base
investig
mechan
iop
fcv
infect
two
hour
pretreat
iop
cell
infect
contribut
resist
fcv
infect
suggest
hose
factor
activ
iop
may
play
import
role
antifcv
infect
howev
treatment
addit
iop
viru
infect
without
pretreat
could
inhibit
fcv
replic
specul
iop
absorb
viru
particl
may
prevent
virus
enter
cell
summari
broadspectrum
antivir
activ
iop
identifi
iop
potent
inhibit
least
five
differ
famili
includ
rna
virus
calicivirida
coronavirida
orthomyxovirida
dna
virus
alphaherpesvirina
parvoviru
studi
requir
investig
vivo
antivir
efficaci
iop
treatment
